Ted Zhang
Portfolio Manager of Turbotection at Revere Asset Management
Hims & Hers, a peptide and GLP-1 play, could make a big move this week because heavy short interest of 33.6% meets a very tight chart setup. After a big move up and a pullback, the stock sits on key longer-term levels and is riding its moving averages, tight enough to structure a trade at 5:1 reward to risk or better. It is a non-traditional setup for this style of trading. x.com
Hims & Hers is at a key support/resistance flip again, and technical risk now points to the upside after months of weakness. With 30% of the float short, the setup could produce a squeeze. x.com
Hims & Hers, alongside Nvidia, has already made the week. x.com
Hims & Hers is going through a major transition period with no growth, so it is not worth owning right now, even though the long-term view remains bullish. x.com
Hims & Hers should benefit as demand for peptides keeps growing faster than people anticipate. Earnings next week may bring some volatility. x.com
Hims & Hers looks bullish after its first open-market insider buy in years, because insiders sell for various reasons but buy for only one. Per @himshouse, director David B. Wells, formerly Netflix's CFO, bought 48.4k shares for $1.2 million. A monthly close above $25 is all Hims & Hers needs. x.com
Heavily shorted stocks like Hims & Hers are generally best avoided unless one can clearly explain why the short thesis is wrong, what would prove it right, and why the upside compensates for the risk. Shorting is expensive and risky and usually done by better-informed institutions, so high short interest often reflects a real bearish case such as bad fundamentals, stretched valuation, dilution risk or a weak balance sheet. Anomalies like GameStop should not be romanticized. x.com
Hims & Hers has enormous long-term potential from its brand, personalized platform and recurring model, and that upside heavily outweighs the bear case. Regulation and customer retention are real questions, and they explain why the opportunity exists. x.com
Hims & Hers is going higher after its report as growth comes back nicely. The EPS miss was mostly a legal contingency charge, a nothing burger, so shares should rise within weeks if not the next day. x.com x.com x.com
Hims & Hers is uninvestable without trust in its management team, and there is absolutely no confidence in it. The stock looked overvalued at $60 before its steep fall; as a popular retail stock it could return to $60 or beyond, but distrust of management rules it out. x.com
Hims & Hers' drop after good news fits a pattern from pharma, the most manipulated sector and now its competition, where multibaggers were often cut down right after good news. Those who sold on the drops were left behind when prices took days, weeks or months to align with the news. x.com
